iRadimed Corp (NASDAQ: IRMD) has reported earnings for its third fiscal quarter (ending September 30) of $0.40 versus $0.40 for the same period a year ago — flat performance. For the latest four quarters through September 30, E.P.S. were $1.47 compared to $1.29 a year ago — an increase of 14%.
Recent Price Action
iRadimed Corp (NASDAQ: IRMD) stock closed at $49.27 on 10/31/24 after a large decline of -6.9%. Moreover, unusually high trading volume at 152% of normal accompanied the decline. The stock has declined -2.4% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
IRMD is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
iRadimed has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. iRadimed has a very low Appreciation Score of 11 but a slightly positive Power Rating of 66, leading to the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment